Clinical trial • Phase III • Other

Petrelintide for Hepatic impairment | Healthy volunteers

Phase III trial of Petrelintide for Hepatic impairment | Healthy volunteers. 36 participants.

Overview

Trial Therapeutic Area
Other
Trial Disease
Hepatic impairment | Healthy volunteers
Trial Stage
Phase III

Key dates

Initial CTIS Submission Date
08-01-2026
First CTIS Authorization Date
06-05-2026

Trial design

Phase III trial across 3 sites in Poland, Slovakia.

Target Sample Size
36

Eligibility

Recruits 36 No vulnerable population selected (isVulnerablePopulationSelected: false). Consent/assent handling not specified..

Vulnerable Population
No vulnerable population selected (isVulnerablePopulationSelected: false). Consent/assent handling not specified.

Recruitment

Planned Sample Size
36
Recruitment Window Months
11

Geography

Total Number Of Sites
3
Total Number Of Participants
36

Poland

Earliest CTIS Part Ii Submission Date
03-04-2026
Latest Decision Or Authorization Date
07-05-2026
Processing Time Days
34
Number Of Sites
1
Number Of Participants
18

Sites

Site Name
Centrum Badan Klinicznych Piotr Napora Lekarze sp.p.
Department Name
Centrum Badań Klinicznych Ośrodek Badań Wczesnej Fazy
Contact Person Name
Piotr Napora
Contact Person Email
napora.piotr@cbk.wroc.pl

Slovakia

Earliest CTIS Part Ii Submission Date
03-04-2026
Latest Decision Or Authorization Date
06-05-2026
Processing Time Days
33
Number Of Sites
2
Number Of Participants
18

Sites

Site Name
Summit Clinical Research s.r.o.
Contact Person Name
Edita Kadlubiaková
Site Name
Summit Clinical Research s.r.o.
Contact Person Name
Viera Kupčová
Contact Person Email
viera.kupcova@summit-cr.eu

Sponsor

Primary sponsor

Full Name
Zealand Pharma A/S
Organisation Type
Pharmaceutical company
Country Of Registered Address
Denmark

Investigational products

Investigational Product Name
Petrelintide
Active Substance
Petrelintide

Related trials

Other published trials that may interest you.